Document Type : Original Article


1 Department of Neurology, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran Neuroscience Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

2 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

3 Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

4 Clinic of Multiple Sclerosis, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

5 Neuroscience Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran


Background: Coronavirus 2019 (COVID-19) vaccination is recommended for people with multiple sclerosis (MS). This study evaluated the side effects of Sinopharm and AstraZeneca vaccines in MS patients.
Methods: In this cross-sectional study among MS patients in Kermanshah province, Iran, who received Sinopharm or AstraZeneca vaccine, sampling was performed through convenience sampling according to the nationwide MS registry of Iran (NMSRI). Demographic and clinical information of the participants and data on the side effects of vaccines were collected by telephone after the first dose. The data were analyzed in SPSS software.
Results: 264 vaccinated MS patients (217 with Sinopharm and 47 with AstraZeneca) were studied. In the Sinopharm and AstraZeneca groups, respectively, 58.5% and 73.3% of patients had side effects that were not significantly different between the 2 groups (P = 0.064). In the AstraZeneca group, the severity of side effects and prevalence of taking painkillers were significantly higher (P < 0.050) and the interval between vaccination and side effects onset was significantly shorter (P = 0.013). 
The most commonly experienced side effects in the Sinopharm group were fatigue (29.0%), myalgia (24.9%), fever (24.0%), and headache (21.7%), and in the AstraZeneca group were fever (59.6%), chills (51.1%), myalgia (40.4%), and fatigue (34.0%). Logistic regression by controlling for confounding variables showed that considering some factors as confounding factors did not show a significant difference between the 2 vaccines in the experience of side effects (P = 0.104).
Conclusion: The AstraZeneca vaccine caused more severe side effects in MS patients than the Sinopharm vaccine. Most of the side effects were moderate in severity and transient.


  1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20(5): 533-4.
  2. Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J 2022; 98(1159): 389-94.
  3. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397(10269): 99-111.
  4. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res 2020; 288: 198114.
  5. Dal-Re R. Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults? Br J Clin Pharmacol 2021; 87(5): 2405-6.
  6. Crasto AM. BBIBP-CorV, Sinopharm COVID-19 Vaccine. New Drug Approvals [Online]. [cited 2021 Apr 23]; Available from: URL:
  7. Baraniuk C. What do we know about China's covid-19 vaccines? BMJ 2021; 373: n912.
  8. Khan R. Cost-effectiveness analysis (CEA) of preventive COVID-19 vaccines by quality-adjusted life years (QALYs). Research Square 2021. [Preprint].
  9. Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Multiple Sclerosis-Associated Intermediate Uveitis. Am J Ophthalmol 2021; 228: 72-9.
  10. Sadeghi BD, Razazian N, Farnia V, Alikhani M, Tatari F, Brand S. Compared to an active control condition, in persons with multiple sclerosis two different types of exercise training improved sleep and depression, but not fatigue, paresthesia, and intolerance of uncertainty. Mult Scler Relat Disord 2019; 36: 101356.
  11. Monschein T, Hartung HP, Zrzavy T, Barnett M, Boxberger N, Berger T, et al. Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. J Neurol Neurosurg Psychiatry 2021; 92(10): 1033-43.
  12. Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 2018; 5(8): ofy174.
  13. Di Filippo M, Cordioli C, Malucchi S, Annovazzi P, Cavalla P, Torri Clerici V, et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry 2022; 93(4): 448-50.
  14. Yamout BI, Zakaria M, Inshasi J, Al-Jumah M, Zeineddine M, Dahdaleh M, et al. MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Mult Scler Relat Disord 2021; 56: 103225.
  15. Lotan I, Wilf-Yarkoni A, Friedman Y, Stiebel-Kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. Eur J Neurol 2021; 28(11): 3742-8.
  16. Shahin S, Eskandarieh S, Moghadasi AN, Razazian N, Baghbanian SM, Ashtari F, et al. Multiple sclerosis national registry system in Iran: Validity and reliability of a minimum data set. Mult Scler Relat Disord 2019; 33: 158-61.
  17. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathol Persa 2021; 7(2): e31.
  18. Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr 2021; 15(5): 102207.
  19. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 2021; 21(7): 939-49.
  20. Jayadevan R, Shenoy R, Anithadevi TS. Survey of symptoms following COVID-19 vaccination in India. medRxiv 2021; 2021.
  21. Riad A, Pokorna A, Attia S, Klugarova J, Koscik M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med 2021; 10(7): 1428.
  22. Allen-Philbey K, Stennett A, Begum T, Johnson AC, Dobson R, Giovannoni G, et al. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Mult Scler Relat Disord 2021; 52: 103028.
  23. Sahraian MA, Ghadiri F, Azimi A, Naser MA. Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV. Vaccine 2021; 39(43): 6347-50.